Magnesium bisglycinate is a dietary supplement of magnesium bound to the amino acid glycine, sold as a well-tolerated way to raise intake. Direct evidence for this form is modest: one trial found a small improvement in self-reported insomnia. Better-known benefits come mostly from cheaper forms. It caused no more digestive upset than placebo; dangerous build-up is a real concern with poor kidney function. Its value rests on correcting low magnesium. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum magnesium | 0.75–0.95 mmol/L | Safety check (high values stop use); expected to rise |
| eGFR (from serum creatinine) | No established target; track change from own baseline | Safety check: declining values reduce or stop use |
| Blood pressure (home, seated) | Below 130/80 mm Hg | Expected to fall; safety check on antihypertensives |
Cadence: Baseline serum magnesium, eGFR and home blood pressure; serum magnesium and eGFR at 8–12 weeks, then every 6–12 months; home blood pressure weekly for the first month on antihypertensives, then monthly; Insomnia Severity Index at baseline and 4 weeks when sleep is the goal; earlier testing after a dose increase, a new interacting drug or symptoms of excess